Naari Pharma Profile
Key Indicators
- Authorised Capital ₹ 86.83 Cr
as on 18-07-2024
- Paid Up Capital ₹ 2.70 Cr
as on 18-07-2024
- Company Age 46 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 88.75 Cr
as on 18-07-2024
- Satisfied Charges ₹ 185.45 Cr
as on 18-07-2024
- Revenue 11.54%
(FY 2023)
- Profit -6139.64%
(FY 2023)
- Ebitda 39.89%
(FY 2023)
- Net Worth -36.70%
(FY 2023)
- Total Assets -16.54%
(FY 2023)
About Naari Pharma
The Corporate was formerly known as Indo Phyto Chemicals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 86.83 Cr and a paid-up capital of Rs 2.70 Cr.
The company currently has active open charges totaling ₹88.75 Cr. The company has closed loans amounting to ₹185.45 Cr, as per Ministry of Corporate Affairs (MCA) records.
Prithipal Kochhar, Deepak Komaregowda, Hermann Osterwald, and One other member serve as directors at the Company.
- CIN/LLPIN
U74899KA1978PTC142872
- Company No.
008881
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 1978
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Naari Pharma Private Limited offer?
Naari Pharma Private Limited offers a wide range of products and services, including Sexual Wellness Products, Contraceptives, Pharma Ingredients & Raw Materials, API (Active Pharmaceutical Ingredients).
Who are the key members and board of directors at Naari Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prithipal Kochhar  | Whole-Time Director | 15-Apr-2015 | Current |
Deepak Komaregowda  | Nominee Director | 06-Dec-2019 | Current |
Hermann Osterwald  | Nominee Director | 10-Oct-2013 | Current |
| Chandrappa Seetharamaiah | Nominee Director | 24-Mar-2018 | Current |
Financial Performance and Corporate Structure Insights of Naari Pharma.
Naari Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.54% increase. The company also saw a substantial fall in profitability, with a 6139.64% decrease in profit. The company's net worth observed a substantial decline by a decrease of 36.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Naari Pharma?
In 2023, Naari Pharma had a promoter holding of 74.40% and a public holding of 25.59%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Symbio Generrics India Private LimitedActive 13 years 6 monthsDeepak Komaregowda is a mutual person
I-Nurture Education Solutions Private LimitedActive 20 years 5 monthsDeepak Komaregowda is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Tata Capital Financial Services Limited Creation Date: 05 May 2022 | ₹2.00 Cr | Open |
Tata Capital Financial Services Limited Creation Date: 27 Dec 2021 | ₹4.00 Cr | Open |
Hdfc Bank Limited Creation Date: 30 Sep 2021 | ₹44.50 Cr | Open |
How Many Employees Work at Naari Pharma?
Naari Pharma has a workforce of 223 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Naari Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Naari Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
